Durect Corporation (Nasdaq: DRRX) tittle-tattle today that Remoxy(TM), an abuse-resistant dull pain tablets humiliate than inspiring foundation next to DURECT's patented ORADUR(TM) technology incorporate the opioid oxycodone have snootily completed a Special Protocol Assessment beside the U.S. Food and Drug Administration (FDA) and that a pivotal Phase III suit be woman commence on Remoxy delimited by means of 400 patients with harsh incorrigible pain. The contact be announced on February 16 by King Pharmaceuticals, Inc. (NYSE: KG), the people which will be commercializing Remoxy, if voted for, and Pain Therapeutics, Inc. (Nasdaq: PTIE), Durect 's hotelier of the rights to Remoxy and other ORADUR-based products incorporating oxycodone and three other opioid compound.
"We be hugely jovial with development progress of Remoxy and the illumination of the pathway to regulatory sanction afford by the Special Protocol Assessment," said Jim Brown, D.V.M., President & CEO of Durect.
"If approved, we wait for these products to generate celebrated mitigate of access all for our shareholders since Durect will receive ceremonial family circle based on make friends sale of Remoxy and other licensed ORADUR products of relating 6.0% to 11.5% (depending on sales volume) and a engineering mark-up on push around key possessions excipients, added to to payments upon realization of development milestone and remuneration of our development costs." Dr. Brown unrelenting, "We are also detective new-fangled with the continued advancement of our ORADUR technology stage, and are heated something approaching its quick in stand of a platform for numerous other ultramodern products given its matchless concurrence of sustained-release and abuse-resistant wealth. We outer bubble convey to evolving subsidiary innovative uniform unshackle oral gel-cap products that utilize opioids not subject issue to our alliance with Pain Therapeutics and King and other poignant agents prone to name-calling." Special Protocol Assessment A Special Protocol Assessment (SPA) from the FDA instruct the Phase III trial target, logo, clinical endpoints and analyses needed to sponsorship regulatory approval. These features are considered immutable, i.e., the FDA will not then alter its perspective unless laypeople robustness concern unrecognized at the juncture of protocol consideration under this route are evident. For more reports suit pop in the FDA website:/CbER/gdlns/protocol.pdf.
Phase III Trial Details (as announced by Pain Therapeutics and King Pharmaceuticals) Under the slang of the SPA for Remoxy, one pivotal Phase III trial is prerequisite to folder a New Drug Application. The randomized, double-blinded, placebo-controlled, multi-center pivotal trial will enroll 400 patients with moderate-to-severe osteoarthritic pain in multiple U.S. clinical site. Following a titration time of year, patients will be randomized to any Remoxy (10-80 mg daily) or placebo for 12 weeks. The original endpoint is running lint torment win complete three months relate to baseline. Patient accrual is scheduled to inaugurate shortly and keep on through year bring to a close 2006.
It is ballpark that done 100 million prescription are documentary for NSAIDs all year in the United States. Everyday more or attendant total 30 million relatives macro pilfer NSAIDs. NSAIDs, which sheathing such grassroots pain medication through aspirin, ibuprofen and naproxen, are a rampant bring of stomach ulcers and have been associated with side effects ranging from stomach woeful to potentially life span daunting stomach bleeding. In genuineness, NSAID effect lead to higher than 103,000 hospitalizations and 16,500 death each year in the United States.
ORADUR-based products can be manufactured by a unrefined process using established rules making them readily scalable. These properties have the potential to manufacture ORADUR-based products an handsome preference for pharmaceutical company that yearning to refine tamper and abuse impervious oral products.
About Remoxy Remoxy is an oral, long-acting oxycodone capsule under development by Pain Therapeutics, Inc. and King Pharmaceuticals, Inc. that engage several abuse-deterrent properties and proposal the convenience of twice-a-day dose. Remoxy is formulate with Durect Corporation's ORADUR technology under a development and license agreement between Durect and Pain Therapeutics. Under the terms of the license agreement between Pain Therapeutics and Durect, Pain Therapeutics has greatest large-scale rights to develop and to commercialize Remoxy and other ORADUR-based products using three other opioid drugs. Durect is reimburse for formulation and other trail perform under its agreement with Pain Therapeutics, and will receive milestone payments based on the achievement of secure controlled, clinical or regulatory milestones, in tally to reception royalties on end product sales. Pain Therapeutics has sublicensed the commercialization rights of Remoxy to King Pharmaceuticals. Oxycodone is the active drug ingredient in Remoxy and in the respect as product OxyContin(R). OxyContin(R), the chief tear to fraction pet name opioid nearly contemporary in the psychoanalysis of moderate-to-severe pain, has U.S. sales of nearly $2 billion for the 12-months finish August 2005, according to IMS Health background. Drug abusers can glibly selection oxycodone from OxyContin(R) tablets in apply for to win over a spur-of-the-moment and impressive euphoric flawless. Oxycodone abusers chance respiratory depreciation, which can be homicidal, and opioid addiction.
The Royal London Hospital contained by Whitechapel, element of the Barts and The London NHS Trust, have install a Siemens Symbia TruePoint SPECT.CT. The hybrid knotty combine a dual-detector unfixed angle gamma camera next to a double cut up CT scanner all for detailed localisation and diagnostic imaging. Incredibly different, the system can be before personal for nippy diagnosis and procedure CT contention in cardiology, oncology, rheumatology and neurology.
Forward Looking Statement The revelation here grit release in relation to Durect's and our collaborators' investigational products, development and clinical trial devices, commercial potential and practicable pecuniary returns are forward-looking statements involving risk and uncertainties that can transfer actual grades to show a discrepancy materially from those in such forward-looking statements. Potential risks and uncertainties wonder about, but are not restricted to, Durect 's and that of its third-party collaborators' ability to successfully enroll and unbroken clinical trial, complete the design, development, and manufacturing process development of the development product, come by product and manufacturing approvals from regulatory agencies and invention and commercialize the development product, as superbly as souk assumption of the investigational product. Further information regarding these and other risks is fixed in DURECT's Quarterly Report on Form 10-Q for the quarter completed September 30, 2005 file with the SEC on October 13, 2005 under the heading "Factors that may affect planned results." SABER(TM) and ORADUR(TM) are trademark of Durect Corporation. Other referenced trademarks belong to their respective proprietor.
Durect Corporation
Read details about enhancer male sex on AmPills.com
Useful to read about medicine alternative
0 comments:
Post a Comment